Pharmafile Logo

Patients and data tracking

- PMLiVE

Incyte/Merck trial failure bodes ill for IDO class

The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

Segmentation, evolved

My research into the evolution of the life science industry reveals broad, sweeping trends, as I wrote about in previous PME articles such as “Selection Pressures” and “Explosive Evolution”. But...

Biogen Idec building

Settlement clears path for Biogen, Samsung’s Humira biosimilar

Agreement could see Europe access Imraldi as early as October this year

- PMLiVE

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

The candidate is expected to start a phase II trial in the coming months

- PMLiVE

FTI Consulting appoints Andrew Ward

He joins the healthcare communications practice as managing director

- PMLiVE

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Both EU and US regulatory advisors are currently assessing the drug

- PMLiVE

IQVIA collaborates with MuleSoft

Will deliver integration technology to life science companies

- PMLiVE

New industry standards group launched

Align Clinical CRO will improve clinical trial collaboration

A critical juncture for clinical data management

Data management functions are handling a much higher volume and diversity of data in response to the increasing scope and demands of global drug development programmes. Real-world data and evidence,...

- PMLiVE

A new era of smart pharma

How smarter pharmaceuticals and pharmacovigilance are transforming healthcare

Celgene building

Celgene boosts CAR-T stake again with Bluebird Bio deal

The US biotech could receive $70m in development milestones for the candidate

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links